A study of oral EMA401 in the treatment of pain following shingles to see if EMA401 can reduce the level of pain.

Registry ID

EUCTR2011-000977-29

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Spinifex Pharmaceuticals Pty Ltd

Start date

2011-07-12

Completion date

2012-07-11

Last update

2026-08-16

Conditions

• postherpetic neuralgia

Summary

To determine the efficacy of EMA401 when administered orally, twice daily (100 mg b.i.d.), in patients with postherpetic neuralgia, as assessed by difference in mean pain intensity score compared to placebo.

Locations

• , , Czechia
• , , Bulgarian Drug Agency

View on source registry